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Introduction
Hypertrophic cardiomyopathy (HCM), the most common genetic cardiomyopathy with an estimated prevalence of 1:200 [1] , is characterized by isolated, asymmetric left ventricular hypertrophy (LVH), diastolic dysfunction and an increased risk on arrhythmias. Mutations in the genes encoding the sarcomeric thick filament components cardiac myosin binding protein-C (cMyBP-C) and β-myosin heavy chain (MYBPC3 and MYH7, respectively) account for~80% of mutations [2] . Two disease mechanisms are described in HCM: 1) poison polypeptides, in which point mutations directly result in changes in protein function, and 2) haploinsufficiency, where the mutated allele produces truncated proteins and the other allele cannot fully compensate. Most HCM-associated MYBPC3 mutations (MYBPC3 mut ) are predicted to lead to truncated proteins [3] . These truncated proteins are suspected to be degraded rapidly since they could not be detected in myectomy samples from HCM patients [4] . This means that all protein which is expressed originates from the healthy allele. The loss of full-length cMyBP-C proteins leads to a reduction of cMyBP-C expression of 30% (i.e. haploinsufficiency) [4] .
It has recently been shown that when expressing a gene, cells transcribe both alleles independently. Allelic transcription occurs in a stochastic manner, where one cell might favor one allele while the next cell favors the other allele and this preference can change over time [5] . This burst-like, stochastic on/off-switching of allele transcription should average out over time, but in case of heterozygosity with protein product of different stability, it can lead to variable expression of healthy and mutant proteins. This was recently shown by Kraft and colleagues [6, 7] . Patients with heterozygous HCM-associated MYH7 gene mutation demonstrated a variable healthy:mutant ratio of mRNA expression in cardiomyocytes from the same heart [6] . This was postulated to result in a variable expression of MYH7 mutant protein. In case of MYBPC3 truncating mutations where the mutant allele does not produce functional protein [4, 8] , averaging out over time does not occur and cell-to-cell differences in cMyBP-C protein expression are expected. The objective of this study was to investigate whether the most common cause of HCM, heterozygous MYBPC3 mutations give rise to a variable myofilament cMyBP-C expression pattern.
Methods

Study population
Studies were performed in septal myectomy samples from six patients with frameshift and missense mutations in MYBPC3 (MYBPC3 mut ) and six sarcomere mutation negative, phenotype positive patients (HCM smn ) (see Fig. 2 for genetic information). All patients were symptomatic with an increased resting left ventricular outflow tract gradient despite optimal medical treatment and were indicated to undergo septal myectomy. All samples were immediately frozen and stored in liquid nitrogen. The study protocol was approved by the local ethics committees, and written informed consent was obtained.
For expanded methods see the Online Supplemental Material.
Results
Study population
The study population consisted of twelve HCM patients (six MYBPC3 mut ; six HCM smn ) who underwent a surgical septal myectomy procedure. MYBPC3 mut were significantly younger and were more often men compared to HCM smn patients (29 ± 7 vs. 61 ± 7 years, p < .001 and 6 males vs. 4 males, p = .02, respectively). Although all patients underwent a septal myectomy procedure to relief left ventricular outflow tract obstruction, MYBPC3 mut subjects demonstrated a significantly higher septal wall thickness compared to HCM smn (28 ± 8 vs. 18 ± 3 mm, p = .02), see Table S1 for additional clinical details.
3.2.
Reduced cMyBP-C protein and mRNA level in cardiac tissue with MYBPC3 mutation MYBPC3 mut patients were heterozygous for frameshift (n = 5) and missense (n = 1) mutations. As shown before [4] , no truncated protein products were detected (Fig. 1A) . Haploinsufficiency was confirmed since total cMyBP-C protein level was significantly lower in MYBPC3 mut compared with HCM smn patients (0.73 ± 0.09 vs. 1.0 ± 0.15, p = .04) (Fig. 1B) . MYBPC3 mut patients revealed a significant lower mRNA level of MYBPC3 gene expression compared with HCM smn (p = .002 for MYBPC3) while ACTC1 expression was unchanged (p = .7, Fig. 1C ).
Immunofluorescence staining of cardiomyocytes
As the truncated protein products of the nonsense MYBPC3 mutations were not detected, any cMyBP-C protein expression present in MYBPC3 mut cardiomyocytes has to originate from the healthy allele. Therefore the protein expression ratio of healthy:mutant allele was quantified by measuring the amount of cMyBP-C. Fig. 2 depicts a representative cardiomyocyte of a HCM smn (panel A) and MYBPC3 mut (panel B) patient. The cardiomyocyte in Fig. 2A demonstrates a homogenous cMyBP-C (white) and α-actin (green) staining, while MYBPC3 mut staining was heterogeneous (Fig. 2B) . Cell width in both patient groups was similar and excluded the possibility that the absence of cMyBP-C staining could be caused by insufficient antibody penetration (see Fig. S4 ). More rod shaped cells were seen in MYBPC3 mut compared to HCM smn (Fig. S5). Fig. 6 of the Supplemental Material shows additional images of cardiomyocytes of cMyBP-C staining in HCM smn and MYBPC3 mut patients.
Cell-to-cell variability of cardiac myosin binding protein-C protein levels in MYBPC3 mut
To quantify the variability of cMyBP-C protein level between cardiomyocytes from the same patient, cMyBP-C:α-actin staining area ratio was measured in 15 to 27 cardiomyocytes per patient, as depicted in Fig. 2C and D . HCM smn patients demonstrate homogenous and equal ratio of cMyBP-C:α-actin ratio of stained area in all cardiomyocytes (Fig. 2C) . In contrast, MYBPC3 mut patients displayed a large intercellular variability of cMyBP-C staining relative to α-actin (Fig. 2D) . The variation of the cMyBP-C staining pattern demonstrated a large difference in staining pattern between MYBPC3 mut compared with HCM smn cells (Fig. S7, panels A, B and C) , and cMyBP-C free patches varied in length (Fig. S7, panel D) . Distribution of cMyBP-C/α-actin stained ratio showed a normal distribution (Fig. S8) .The variation in ratio of cMyBP-C/α-actin stained area per cell per patient was quantified by determining the coefficient of variance of cMyBP-C/α-actin ratio for each patient. This demonstrated a significant difference in variation of protein expression between the cardiomyocytes in both patient groups (5.18 ± 0.65 vs. 17.30 ± 4.08%, p = .02) (Fig. 2E ).
Discussion
This is the first study to demonstrate intercellular variation of cMyBP-C myofilament protein expression due to mutations in MYBPC3 within the myocardium from HCM patients.
The concept underlying variable expression is that a cell predominantly transcribes one allele of a gene, which is "chosen" at random, which was demonstrated by single cell sequencing [9] . In healthy subjects it does not matter from which allele a cell transcribes its protein as this process occurs stochastically. In case of a mutant allele and a wild-type allele (such as in heterozygous HCM patients), this will lead to a certain number of cardiomyocytes with a relatively high level of mutant protein and other cardiomyocytes with very little mutant protein. This was recently shown to occur at the mRNA level in the MYH7 R723G mutation [6] . As MYH7 mutations are point mutations, this variable expression pattern was not validated on protein levels yet. Western blot analysis in this study confirmed previous findings that the truncated protein products of the mutated allele are degraded in the cardiac tissue [10] (Fig. 1A) .
The amount of healthy cMyBP-C in a MYBPC3 mut cardiomyocyte is the result of the amount of transcription from the healthy allele, the translation efficiency and the protein turnover rate. Helms and colleagues demonstrated a paradoxical upregulation of mRNA in samples with truncating mutations, which was assumed to be a compensatory mechanisms as an attempt to maintain full-length cMyBP-C [11] . However, we observed a decreased expression of cMyBP-C at mRNA and protein level in MYBPC3 mut confirming previous observations [4, 8] . In accordance, transduction of full-length and truncating mutant MYBPC3 in engineered heart tissue, to mimic a heterozygous mutation, showed cMyBP-C haploinsufficiency [12] . It has recently been shown by Lewis and colleagues that for maintenance of the sarcomere, a highly defined spatial control of protein translation and degradation is present [13] . They showed that at individual sarcomeres throughout the cell, protein translation and degradation machinery was present. In MYBPC3 mut we know that transcription and therefore translation of MYBPC3 is impaired, but also that there are changes in protein degradation, and therefore turnover [14] . Changes in microtubule architecture are known to occur in HCM [15] , which are important for delivery of the translation and degradation machinery throughout the cell [13] . The loss of spatial control of protein translation and degradation in conjunction with the lower levels of transcription likely all contribute to the diverse cMyBP-C staining patterns observed in the cardiomyocytes from MYBPC3 mut . In HCM smn homogeneous expression of cMyBP-C with low levels of cell-to-cell variation were seen, indicating that the observed effects are specific for MYBPC3 mutations. These observations are in line with staining patterns of cMyBP-C protein throughout cardiomyocyte from HCM patients with MYBPC3 mutations. Cells with MYBPC3 mutation demonstrated greater disruption in staining of thick filament proteins compared to MYH7 mutations [16] . The experiments performed in this study utilized immunofluorescence analysis on mechanically isolated single cells. With the current analysis we were not able to quantify haploinsufficiency in individual cardiomyocytes, as we did in cardiac tissue (Fig. 1) . The functional consequences of this variable expression of cMyBP-C remain to be determined. Loss of cMyBP-C in mouse studies have shown that severe cardiac dysfunction occurs [17] . It may be speculated that intercellular variation of cMyBP-C protein levels lead to inhomogeneous contraction and relaxation and may be involved in the formation of myofibrillar disarray (Fig. 2F) . As aging reduces the quality of protein degradation pathways and increases the degree of allelic imbalance in cardiomyocytes [18] , an age-dependent progression of cellular protein variability may contribute to HCM development.
Conclusion
This is the first study which demonstrates the intercellular variation of cMyBP-C myofilament protein levels in cardiomyocytes of MYBPC3 mut patients.
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